Shattuck Labs

Shattuck Labs is a biotechnology company developing an antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and commitment to pursuing the development of novel therapeutics targeting TNF receptors come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve complete and more durable blockades of the clinically validated TL1A/DR3 pathway.

Additional Details

Company Size:

50-99 Employees

Headquarters:

Austin, Texas